HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Colgate Looks To Aging Gums, Whitening Launches For Growth In 2012

This article was originally published in The Rose Sheet

Executive Summary

Colgate-Palmolive plans oral-care launches in 2012 aimed at aging consumers seeking gum protection as well as consumers looking for “a shinier, sparkling smile.” Firm reports fiscal 2011 sales of $16.7 billion, up 7.5% from the year prior.

You may also be interested in...



Colgate Hikes Prices, Expects To Hit EPS Growth Target In 2011

Colgate-Palmolive plans to raise prices on products across its portfolio and in all geographies, President and CEO Ian Cook told analysts April 28.

Roche Continues To Make The Case For Gantenerumab In Alzheimer’s Disease

The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.

Brinavess' US Review: EU Postmarket Data Unlikely To Save Troubled AFib Drug

Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug;  FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.

Related Companies

UsernamePublicRestriction

Register

RS017942

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel